GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » Cash Ratio

Algernon Pharmaceuticals (XCNQ:AGN) Cash Ratio

: 0.03 (As of Nov. 2023)
View and export this data going back to 2016. Start your Free Trial

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Algernon Pharmaceuticals's Cash Ratio for the quarter that ended in Nov. 2023 was 0.03.

Algernon Pharmaceuticals has a Cash Ratio of 0.03. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Algernon Pharmaceuticals's Cash Ratio or its related term are showing as below:

XCNQ:AGN' s Cash Ratio Range Over the Past 10 Years
Min: 0.03   Med: 6.49   Max: 128
Current: 0.03

During the past 9 years, Algernon Pharmaceuticals's highest Cash Ratio was 128.00. The lowest was 0.03. And the median was 6.49.

XCNQ:AGN's Cash Ratio is ranked worse than
96.26% of 1525 companies
in the Biotechnology industry
Industry Median: 2.97 vs XCNQ:AGN: 0.03

Algernon Pharmaceuticals Cash Ratio Historical Data

The historical data trend for Algernon Pharmaceuticals's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Cash Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 10.08 2.36 0.56 0.05

Algernon Pharmaceuticals Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Cash Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.09 0.18 0.05 0.03

Competitive Comparison

For the Biotechnology subindustry, Algernon Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algernon Pharmaceuticals Cash Ratio Distribution

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Cash Ratio falls into.



Algernon Pharmaceuticals Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Algernon Pharmaceuticals's Cash Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash Ratio (A: Aug. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.125/2.72
=0.05

Algernon Pharmaceuticals's Cash Ratio for the quarter that ended in Nov. 2023 is calculated as:

Cash Ratio (Q: Nov. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.074/2.939
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals  (XCNQ:AGN) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Algernon Pharmaceuticals Cash Ratio Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals (XCNQ:AGN) Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (XCNQ:AGN) Headlines

No Headlines